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Introduction: Acquired cancer therapy resistance evolves
under selection pressure of immune surveillance and favors
mechanisms that promote drug resistance through cell
survival and immune evasion. AXL receptor tyrosine kinase
is a mediator of cancer cell phenotypic plasticity and sup-
pression of tumor immunity, and AXL expression is asso-
ciated with drug resistance and diminished long-term
survival in a wide range of malignancies, including NSCLC.
Methods: We aimed to investigate the mechanisms under-
lying AXL-mediated acquired resistance to first- and third-
generation small molecule EGFR tyrosine kinase inhibitors
(EGFRi) in NSCLC.
Results: We found that EGFRi resistance was mediated
by up-regulation of AXL, and targeting AXL reduced
reactivation of the MAPK pathway and blocked onset
of acquired resistance to long-term EGFRi treatment
in vivo. AXL-expressing EGFRi-resistant cells revealed
phenotypic and cell signaling heterogeneity incompatible
with a simple bypass signaling mechanism, and were
characterized by an increased autophagic flux. AXL kinase
inhibition by the small molecule inhibitor bemcentinib or
siRNA mediated AXL gene silencing was reported
to inhibit the autophagic flux in vitro, bemcentinib
treatment blocked clonogenicity and induced
immunogenic cell death in drug-resistant NSCLC in vitro,
and abrogated the transcription of autophagy-associated
genes in vivo. Furthermore, we found a positive correlation
between AXL expression and autophagy-associated gene
signatures in a large cohort of human NSCLC (n ¼ 1018).
Conclusion: Our results indicate that AXL signaling sup-
ports a drug-resistant persister cell phenotype through a
novel autophagy-dependent mechanism and reveals a
unique immunogenic effect of AXL inhibition on drug-
resistant NSCLC cells.
 2020 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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EGFR TKI resistance; Phenotypic plasticity; Tumor immune
microenvironment; Autophagic fluxIntroduction
Acquired therapy resistance to oncogene-targeted
cancer therapeutics invariably diminishes long-term
clinical outcome, and the lack of efficacy of immune-
based therapy in oncogene-driven tumors limits
treatment options for patients with recurrent tumors.
Molecular analysis reveals that relapsing tumors utilize
both genetic and nongenetic resistance mechanisms,including additional gene mutations that could abrogate
or bypass drug-target interactions and affect epigenetic
reprogramming mechanisms that would alter the
expression of various drug targets involved in cell
survival.1 In lung adenocarcinomas with activating
EGFR mutations, secondary mutations in the EGFR
tyrosine kinase domain (T790M) are detected in 50%
to 60% of tumors displaying acquired resistance to
first-generation EGFR tyrosine kinase inhibitors
(TKIs).2-5 In addition, bypass signaling through MET
gene amplification or epistatic gene activating muta-
tions in downstream signaling proteins (e.g., MAPK/
PI3K) can also restore the oncogenic driver signaling,
and these two phenomena are considered to be the
main acquired resistance mechanisms to EGFR TKIs.
Nonmutational acquired resistance through induced
cellular phenotypic plasticity, including epithelial-to-
mesenchymal transition (EMT) and small cell trans-
differentiation, represents an alternative mode of drug
resistance that relies on epigenetically regulated
phenotypic transition to an EGFR-independent cellular
state.6 Enhanced stem cell–like features allowing
adaptation to dynamic tumor microenvironments
frequently accompany this cellular transition. However,
the early events leading to acquired resistance are less
thoroughly understood, and an outstanding question
remains as to whether an epigenetically regulated drug
tolerant state, triggered by prolonged drug exposure,
precedes the emergence of permanent drug resistance
through the manifestation of genetic resistance mech-
anisms.7 This drug tolerant state is suggested to entail
drug-induced epigenetic and transcriptional reprog-
ramming mechanisms.8 A post-treatment tumor
microenvironment that selects for a drug-resistant
phenotype comprises cell debris from dying tumor
cells and pro-inflammatory mediators derived from
macrophages.9 The importance of reversible transcrip-
tional reprogramming in the development of acquired
drug resistance was recently reported by Shaffer and
colleagues,10 who reported that rare melanoma cells in
culture are transiently poised to undergo drug-induced
epigenetic reprogramming and thus may represent the
source of subsequent drug-resistant colonies.10 Of note,
these cells were characterized by high levels of AXL and
other genes with known associations to drug resistance
and are further referred to as “AXL jackpot cells.”10
Thus, accumulating evidence indicates that AXL
signaling may uniquely contribute to an early pro-
survival state that seems to be a prerequisite for the
subsequent development of acquired resistance.
Correspondingly, elevated expression of AXL has been
reported in a wide range of cancers, including NSCLCs,
and has been associated with aggressive clinical
behavior and drug resistance.11-15
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cytoplasmic vacuoles are shuttled to lysosomal com-
partments for bulk degradation, is increasingly recog-
nized as a pro-survival mechanism for cells in response
to intrinsic and extrinsic stress, and autophagy is
frequently exploited by neoplastic cells during cancer
progression.16 EMT has been associated with increased
autophagy and tumor progression and may allow
cancer cells to overcome microenvironmental stress,
and also to escape immune surveillance by cytotoxic
T-lymphocytes.17-20 We have recently shown that EMT,
and in particular expression of AXL, in NSCLC cells is
correlated with increased cancer cell–intrinsic resistance
to both natural killer (NK)– and cytotoxic T-lymphocyte
(CTL)–mediated killing.21 We hypothesized that a small
molecule drug targeting AXL could sensitize mesen-
chymal lung cancer cells to cytotoxic lymphocyte–
mediated killing, and we subsequently reported that
targeting AXL overcomes NSCLC resistance to NK– and
CTL–mediated cytotoxicity.21
The antitumor efficacy of widely used cancer treat-
ment strategies, including common chemotherapies, ra-
diation, and more selective targeted approaches has
been attributed, in part, to the induction of immunogenic
cell death (ICD).22 ICD inducer screening supports the
contention that Food and Drug Administration–approved
anticancer agents are more likely to promote ICD than
approved agents from remaining non-oncology phar-
macologic specialties.23 Cancer cells undergoing ICD
elicit immunostimulatory capacity owing to the spatio-
temporally defined release of potent danger signals,
referred to as danger- or damage-associated molecular
patterns (DAMPs), also known as alarmins.22 Of note,
three DAMPs, in particular, have been reported to play a
crucial role in the immunogenic potential of nearly all
ICD inducers identified thus far22: (1) the translocation
of calreticulin (CALR) from the endoplasmic reticulum to
the outer leaflet of the plasma membrane, (2) pre-
mortem autophagy-dependent release of the “find me”
signal adenosine triphosphate (ATP), and (3) the passive
release of the high-mobility group box 1 (HMGB1) nu-
clear protein. When successfully induced, ICD could
provide the adjuvant immunostimulatory signals neces-
sary for long-term protection against recurrence and
metastasis of carcinoma cells caused by the activation of
protective immunity. Premortem stress-related auto-
phagy can drive an immunogenic form of cell death,
indicating that an increased autophagic flux can be
exploited to bridge the innate and the adaptive immune
system, and may be a critical determinant of immune-
related therapy-induced cancer cell death.24 A high
premortem autophagic flux is a prerequisite for the
accumulation of ATP, one of the alarmins critical for
induction of ICD.25AXL signaling mediates acquired resistance to EGFR
tyrosine kinase inhibition by driving a pro-survival
pathway in NSCLC cells. In the current study, we
report that targeting AXL with the small molecule in-
hibitor bemcentinib delayed the onset of resistance to
EGFR inhibition and affected the transcription of
autophagy-associated gene signatures in vivo, whereas
in vitro the apoptosis resistance of NSCLC cells that were
resistant to the EGFR TKI erlotinib was attributed to
their high autophagic flux. Furthermore, in samples from
a large human cohort of NSCLC (n ¼ 1018) we found a
positive correlation between AXL expression and
autophagy-associated gene signatures, which supports
the clinical relevance of our findings. We hypothesized
that the high premortem autophagic flux of the AXL-
expressing cells could be exploited in a therapeutic
setting for EGFRi–resistant NSCLC tumors because the
release of the alarmin ATP from dying autophagic cells
would be expected to kick-start the cancer immunity
cycle. Here, we report for the first time that targeted
inhibition of AXL signaling by bemcentinib abrogates this
high premortem autophagic flux in NSCLC cells resistant
to first- and third-generation EGFR inhibitors and thus
enhances tumor immunogenicity through the release of
DAMPs while undergoing an immunogenic form of cell
death. Thus, our data reveal a novel link between AXL,
autophagy, and tumor immunogenicity.
Materials and Methods
Drugs
Erlotinib hydrochloride salt (E-4007, LC Labora-
tories, Woburn, Massachusetts), bemcentinib (BGB324/
R428, BerGenBio ASA, Bergen, Norway), rociletinib (CO-
1686, Clovis Oncology, Boulder, CO), staurosporine
(ab120056, Abcam, Cambridge, United Kingdom), bafi-
lomycin A (B1793, Sigma-Aldrich, St. Louis, Missouri),
and rapamycin (R8781, Sigma-Aldrich) were prepared in
DMSO for in vitro studies. Erlotinib and bemcentinib
were prepared in 0.5% (w/w) hydroxypropyl methyl-
cellulose/0.1% (w/w) Tween-80 for in vivo adminis-
tration. Chloroquine diphosphate (ab142116, Abcam)
was dissolved in water.
Cell Culture
The human NSCLC epithelial cell line HCC827 (CRL-
2868, ATCC, Manassas, Virginia) has an activating EGFR
mutation (E746–A750 deletion) that engenders sensi-
tivity to erlotinib. HCC827 cells were maintained in
RPMI-1640 medium (R8758, Sigma-Aldrich) containing
5% heat-inactivated fetal bovine serum (FBS) (Gibco),
20 U/mL penicillin, 20 mg/mL streptomycin (penicillin-
streptomycin, P-0781, Sigma-Aldrich) and 2 mM
L-glutamine (G-0781, Sigma-Aldrich) at 37C, 5% CO2,
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bator (MCO-5M-PE, Panasonic, Osaka Prefecture,
Japan). Erlotinib-resistant clones (ER3 and ER10)
derived from HCC827 parental cells were established
in vitro by culture in increasing concentrations of
erlotinib, as described previously.14 The ER3 cells were
established in Professor Trever G. Bivona’s laboratory
(UCSF, California), whereas the ER10 cells were
established in Professor Henrik J. Ditzel’s laboratory
(University of Southern Denmark, Odense, Denmark).
Erlotinib-resistant cells were maintained in culture in
the presence of 1 mM erlotinib. The human NSCLC cell
line H1975 and two rociletinib (CO-1686)-resistant
(COR) cell clones (COR1-1 and COR10-1) were pro-
vided by Clovis Oncology.26 H1975 cells were cultured
in the same way as HCC827 cells and rociletinib-
resistant clones were maintained in culture with 1
mM rociletinib. Cell lines were routinely tested for
Mycoplasma contamination using the MycoAlert My-
coplasma Detection Kit (LT07-218, Lonza, Basel,
Switzerland). All cell lines used in these studies were
authenticated by short tandem repeat (STR) profiling
using the LGC service Promega’s PowerPlex 18D Sys-
tem. The AACR STR database (135-XV-5, ATCC) was
applied as a reference for authentication of STR
profiles.Animal Studies
Animal experiments were approved by the Institu-
tional Animal Care Research Authority and in accordance
with the European convention for the protection of
vertebrates used for scientific purposes. Animals were
housed in a germ-free environment in filter top cages.
Environmental parameters were monitored by the Lab-
oratory Animal Facility at the University of Bergen
following institutional standard operating procedures.
Animals were provided certified laboratory feed and
sterile drinking water ad libitum. Athymic Nude-Foxn1nu
mice 6 to 8 weeks old were obtained from Harlan Lab-
oratories (Horst, The Netherlands). For xenograft
studies, 8 million HCC827 cells (at least 95% viable as
determined by Tryphan Blue exclusion test) in 1:1
nonsupplemented RPMI1640 medium and Matrigel
(Matrigel Basement Membrane Matrix Growth Factor
Reduced, BD Biosciences, San Jose, CA) were implanted
subcutaneously into the right and left flank of female
nude mice. Randomization was conducted using the
Latin square method on the basis of total tumor volume
of each animal. Randomization of animals was per-
formed so that the average tumor volume for all treat-
ment groups (eight animals per group) was
approximately 110 mm3. Bemcentinib was administered
twice a day at a concentration of either 50 mg/kg or 100mg/kg by oral gavage. Erlotinib was administered once a
day at 50 mg/kg by oral gavage. Tumor growth was
measured two to three times weekly with digital hand-
held calipers, and tumor volumes were calculated using
the formula (L x W x W)/2. For the 50 mg/kg
bemcentinib þ 50 mg/kg erlotinib group, one tumor was
identified by the Grubbs test (description under Methods
section of Statistics) as a statistically significant outlier
(p < 0.01). This tumor was eliminated from further
analysis. Clinical observations of animal appearance and
body weight measurements were recorded daily, and
tumor measurements were performed two to three
times weekly. In general, a decrease in body weight
greater than 20% would indicate toxicity and should
lead to euthanization of mice. None of the treatment
groups had reduction in body weight which would be
indicative of toxicity. At study termination, the animals
were anesthetized by sevoflurane and euthanized by
cervical dislocation following institutional standard
operating procedures.Gene Expression Analysis
On the day of study termination (after 25 d of treat-
ment), animals were euthanized, and harvested tumors
were snap-frozen in liquid nitrogen and stored in a ni-
trogen tank. Total RNA from HCC827 tumors were iso-
lated with RNeasy Mini columns (Qiagen, Hilden,
Germany) and RNA integrity was evaluated using a Bio-
analyzer instrument (Agilent Technologies, Santa Clara,
CA). Gene expression arrays were performed at the ge-
nomics core facility at the University of Bergen. Gene
expression levels were measured by hybridization to
Illumina Human HT-12 v4 Expression BeadChip arrays
and analyzed in GeneStudio and J-Express Pro (http://
jexpress.bioinfo.no). Four samples were excluded on the
basis of poor quality control data (one vehicle, two
erlotinib-treated, one combination-treated). Significance
analysis of microarray data (J-Express Pro) was used to
generate a list of up- and down-regulated genes in
erlotinib-treated versus combination-treated tumorswith
associated fold change and significance calculations. Sig-
nificance analysis of microarray whole-ranked lists were
used for gene ontology analyses by employing GOrilla
software (http://cbl-gorilla.cs.technion.ac.il). A volcano
plot was generated to display changes in gene expression
versus significance (log2[fold change] versus –log10[p
value]) between HCC827 tumors treated for 25 days
either with erlotinib alone (50 mg/kg, once a day) or a
combination of erlotinib (50 mg/kg, once a day) and
bemcentinib (50 mg/kg, twice a day), n ¼ 4. KM-plotter
was used to assess the effect of sprouty genes (SPRY1,
SPRY2, and SPRY4) on NSCLC survival (http://kmplot.
com/analysis/).
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For 96-well plate viability assays, 1000 cells per well
were seeded and allowed to attach overnight. The next
day, treatment was added in fresh cell medium containing
varying concentrations of erlotinib (5083S, Cell Signaling
Technology) or rociletinib (Clovis Oncology) alone, or in
combination with bemcentinib (BerGenBio). After 5 days
of treatment, the cell viability was measured by incu-
bating with resazurin (25 mg/mL, R-7017, Sigma-Aldrich)
for 3 hours at 37C, 5% O2, 5% CO2, and fluorescence was
measured for 1 second at 560Ex/590Em in a 1420 Multi-
label Counter VICTOR3 (Perkin Elmer, Waltham, Massa-
chusetts) using the Wallac 1420 software. Background
fluorescent signal was removed by subtracting the mean
value of fluorescence from blank wells containing only
cell culture medium and resazurin, and the cell viability
was normalized against vehicle (DMSO) control.
Cell viability for the assessment of drug synergism
was calculated using the Bliss independence model.27
Delta Bliss values were calculated as expected cell
death (fold change) from the combined therapy minus
observed cell death (fold change) at the same concen-
trations. The Bliss sum is then calculated as the sum of
all delta Bliss values for all the different drug combina-
tions in one experiment. Negative delta Bliss values
indicate synergy; positive delta Bliss values indicate that
the drugs are working as antagonists, whereas delta
Bliss values close to zero indicate that the drugs are
acting independently. Cell death was calculated as (one-
cell viability [fold change]), and a mean value of six
parallels was used for further analysis. Assuming that
the drug response from erlotinib and bemcentinib are
mutually independent, the expected cell death from
treatment with a combination of erlotinib and bemcen-
tinib at concentration i and j (EErliBemj) was calculated
using the formula: EErliBemj ¼ EErli þ EBemj  EErli 
EBemj ; where EErli is the observed cell death for erlotinib
treatment at concentration i and EBemj is the observed
cell death at bemcentinib concentration j, and i and j are
all drug concentrations used in the experiment.27Clonogenic Assay
Clonogenic assays were performed according to a
protocol adapted from Franken et al.28 Briefly, cells were
detached and counted with a Nucleocounter NC-100
(Chemometec, Allerod, Denmark) and the number of
viable cells per mL was calculated. Subsequently, 1000
viable single cells were plated per well in six-well cell
culture plates. Cells were allowed to attach for 16 hours
before initiation of treatment and cells in three replicate
wells were treated per condition. The cells were treated
as indicated for 14 days before fixation and staining by
incubation in a mixture of 25% methanol and 0.01%crystal violet for 30 minutes at room temperature.
Crystal violet binds to DNA in the nuclei of mammalian
cells, staining them a deep purple and helping to visu-
alize colonies. On removal of the fix and stain solution,
the cells were rinsed carefully and immersed in running
tap water. The colonies were allowed to dry in normal
air at room temperature overnight before imaging by an
EPSON Perfection V850 Pro scanner (Epson, Suwa,
Japan). Clonogenic assays were quantified using the
“ColonyArea” plugin29 for ImageJ.30 Each experiment
was independently repeated three times and the results
revealed the mean colony area (%) ± SD from a repre-
sentative experiment.Caspase 3/7 Luminescence Assay
For determination of induced apoptosis in treated
cells, Caspase-Glo 3/7 luminescence-based assay
(G8092, Promega, Madison, Wisconsin) was used ac-
cording to the manufacturer’s instructions. Briefly, 5000
cells per well were seeded in a 96-well plate and incu-
bated overnight before treatment, as indicated, in 100 mL
culture medium. For the assay, 50 mL cell medium was
removed and 50 mL Caspase-Glo reagent was added per
replicate. The content was mixed by gently shaking the
plate for 30 seconds, and the plate was incubated at
room temperature for 1 hour before measuring lumi-
nescence for 0.1 second in a Perkin Elmer 1420 Multi-
label Counter VICTOR3 (Perkin Elmer) using the
Wallac1420 software. Two-way analysis of variance
(ANOVA) was followed by Dunnett’s t test comparing the
treated cells against the vehicle control for each cell line.Western Blotting
Tumor material harvested after 51 days of treatment
was lysed in radioimmunoprecipitation assay (RIPA)
buffer (phosphate buffered saline [PBS] with 1% [vol/vol]
NP-40, 0.5% [wt/vol] sodium deoxycholate, and 0.1%
[wt/vol] sodium dodecyl sulfate [SDS]) supplemented
with protease and phosphatase inhibitor tablets (Roche,
Basel, Switzerland) and 0.2 mM phenylmethylsulfonyl
fluoride. In vitro cell cultures were treated as indicated
and washed with ice-cold PBS, scraped in PBS on ice,
collected by centrifugation, and lysed in RIPA buffer (sc-
24948A, Santa Cruz Biotechnology, Dallas, Texas). Protein
concentration was measured using a Pierce BCA Protein
Assay Kit in accordance with manufacturer’s instructions
(23225/23227, Thermo Fisher Scientific, Waltham, Mas-
sachusetts). Lysates were dissolved in water with
BIO-RADxT sample buffer (1610791, Bio-Rad, Hercules,
California) and incubated for 5 minutes at 90C. The
samples were then centrifuged and 10 to 20 mg protein
loaded per well on 4% to 20% Mini-PROTEAN TGX Stain-
FreeGels (4561096,Bio-Rad). Theproteinswere separated
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V for 1 hour. The stain-free gels were then activated by 2.5
minute-exposure to ultraviolet light (ChemiDoc XRSþ, Bio-
Rad) to allow total protein quantification. Semidry blotting
to a transblot turbo mini-size low fluorescence poly-
vinylidene fluoride membrane (1704156, Bio-Rad) was
performed using the Bio-Rad Trans-Blot system (2.5 A, 25
V, 7 min). Tris-glycine-SDS buffer (1610772, Bio-Rad) was
used for the transfer. Images of the total protein amount of
the membrane were obtained directly after the transfer
and these imageswere later used for normalization against
total protein and further quantifications of Western blots
as described for stain-free gels by the manufacturer
(ChemiDoc XRSþ, Bio-Rad). Membranes were blocked
with 5% bovine serum albumin (BSA) (A2058, Sigma-
Aldrich) or 5% nonfat dry milk (170-6404, Bio-Rad) in
tris-buffered saline with 0.1% polysorbate 20, then incu-
bated with primary antibody overnight at 4C (see
Supplementary Table 2A). Membranes were washed three
times for 5 minutes with tris-buffered saline and 0.1%
polysorbate 20, and incubated for 1 hour at room tem-
perature with one-to-10,000 ratio of goat anti-mouse
horseradish peroxidase labeled (170-6516, Bio-Rad) or
goat anti-rabbit horseradish peroxidase labeled (170-
6515, Bio-Rad) secondary antibodies. Chemiluminescent
substrate was added (Super Signal West Femto Maximum
Sensitivity Substrate, 34095, Thermo Fisher Scientific) and
chemiluminescence was measured by a Molecular Imager
ChemiDoc XRSþ (Bio-Rad). ImageLab v5.0 (Bio-Rad) soft-
warewasused for analysis andquantificationof the results.
Quantification of Western blot results are presented as
chemiluminescent signal normalized against total protein,
as described by Gürtler et al.31 Although not used for
quantification per se, a housekeeping protein (actin, b-
actin, or glyceraldehyde 3-phosphate dehydrogenase) are
shown as loading controls in all figures to improve instant
interpretability for readers.
Mass Cytometry
Antibody Panel. An antibody panel was designed to
include antibodies against some of the major signaling
proteins downstream of the AXL-EGFR pathways. Avail-
able data on heavy metal signal overlap were used to
minimize spillover using the Fluidigm MaxPar Panel
Designer. All antibodies were previously verified and
described by Pelissier Vatter et al.,32 or commercially
available and verified by Fluidigm. Phospho-antibodies
were titrated using lambda-phosphatase–treated cells
as a negative control (data not shown). An overview of
the antibodies and antibody concentrations is given in
Supplementary Table 2B.
Sample Preparation and Data Acquisition. Cells were
detached using 2 mL TrypLE Express Enzyme(12604021, ThermoFisher Scientific) per T75 flask. Cells
were exposed to TrypLE at 37C until the cells had
completely detached (approximately 5 minutes), and
then TrypLE was inactivated by adding 8 mL complete
cell medium. Approximately, 2 million cells per sample
were resuspended in 1 mL Cell-ID Cisplatin 194-Pt
(1:2000 dilution in PBS, stock concentration; 1 mM,
201194, Fluidigm, South San Fransisco, CA) and incu-
bated for 1 minute at room temperature; 9 mL serum-
free cell medium was then added, and the cells were
collected by centrifugation. Cells were resuspended in 1
mL 1.6% paraformaldehyde (PFA) (15710, Electro-
nMicroscopySciences) in serum-free medium, and incu-
bated for 10 minutes at room temperature. The cells
were then spun down and the samples was stored at
–80C until use (< 2 mo). Each sample was washed with
200 mL Maxpar Barcode Perm buffer (201057, Fluidigm),
collected by centrifugation and then resuspended in 195
mL Maxpar Barcode Perm buffer. Five microliters of
barcoding solution (Cell-ID 20-Plex Pd Barcoding kit,
201060, Fluidigm) was added and the cells were incu-
bated in this solution for 30 minutes at room tempera-
ture. Then, the samples were washed two times with 200
mL Maxpar Barcode Perm buffer, followed by one wash
with 1 mL cell staining buffer (CSB) (201068, Fluidigm)
and one wash with 1 mL 1% BSA (A9647, Sigma-Aldrich)
containing 1x DNAse (DN25, Sigma-Aldrich) in Dulbec-
co’s PBS (14040-153, ThermoFisher Scientific). Samples
were pooled into one sample tube and permeabilized
with 1 mL ice-cold methanol for 20 minutes at –20C.
The cells were then washed two times with 1 mL CSB
and stained with antibody mixture (Supplementary
Table 2B) dissolved in 300 mL CSB for 1 hour at room
temperature. The sample was then washed three times
in 1 mL CSB, one time in 1 mL PBS (201058, Fluidigm),
and then incubated with 1 mL 1.6% PFA in PBS with 0.3
mL Cell-ID Intercalator Iridium (201192B, Fluidigm)
overnight at 4C. The next day, the sample was washed
once with PBS, incubated 10 minutes at room tempera-
ture in 1 mL 1% BSA containing 1 DNAse in Dulbecco’s
phosphate buffered saline, washed twice with 1 mL PBS,
twice with 1 mL MilliQ water, and dissolved in MilliQ
water with EQ Four Element Calibration Beads (201078,
Fluidigm) at a concentration of approximately 1 million
cells per mL. The sample was then analyzed using a
Helios mass cytometer (Fluidigm).
Data Analysis. Data was normalized and debarcoded
using the CyTOF software (Fluidigm). For the debar-
coding, the minimum barcode separation was set to 0.14
and the maximum Mahalanobis distance was set to
three; the rest of the settings were kept as default. Cells
were gated as iridium positive events, and cisplatin
staining was used to discriminate dead cells. Iridium
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from single cells. After gating, signal from approximately
100,000 viable and single cells per sample were included
in the histograms (Supplementary Fig. 4). ViSNE, a
visualization tool for high-dimensional single-cell data,
which is based on the t-Distributed Stochastic Neighbor
Embedding (tSNE) algorithm,33 was then applied using
the Cytobank software with the following settings:
downsampling; equal sampling; 10,000 cells per sample,
5000 iterations, perplexity: 30, theta: 0.5, seed: random
(1730472643), channels used in tSNE: E-cadherin
(CDH1), vimentin (VIM), CD44, EGFR, AXL, and pro-
grammed death-ligand 1.Immunofluorescence and Confocal Imaging
Immunocytochemistry for the Characterization of
EMT Markers. For immunocytochemistry, 20,000 cells
per well was plated on crystal-clear German glass cov-
erslips with Poly-D-lysine coating (Neuvito Corporation,
Vancouver, Washington) in a 24-well cell culture plate
and allowed to attach overnight. Cells were washed in
PBS and fixed with 3.7% formalin for 15 minutes at
room temperature. The cells were then washed again
with phosphate buffered saline containing 0.1% Tween-
20 (PBS-T), permeabilized with 0.3% Triton X-100 for 20
minutes, and blocked with 5% goat serum (G9023,
Sigma-Aldrich) for 1 hour at room temperature. Incu-
bation with primary antibody against E-cadherin (CDH1,
14472S, Cell Signaling Technology, 1:100) and vimentin
(VIM, ab92547, Abcam, 1:100) overnight at 4C was
done, followed by washing and 1 hour of incubation with
secondary antibodies (goat anti-mouse AF488, 1:200,
A11029, Invitrogen and goat anti-rabbit AF546, 1:200,
A11035, Invitrogen, Carlsbad, California) at room tem-
perature. Cells were washed again and mounted with
ProLong Diamond Antifade Mountant with 40,6-
diamidino-2-phenylindole (DAPI) nuclear counterstain
(P36962, Molecular Probes, Eugene, Oregon). Images
were obtained on a Leica TCS SP5 confocal microscope
(Leica, Wetzlar, Germany) using a 63 objective lens
magnification (HCX PL Apo Cs, oil, NA ¼ 1.4, WD ¼ 0.1
mm).Immunocytochemistry for the Co-Localization of LC3
Puncta and LysoTracker. Cells were treated with
various drug combinations as indicated for 7 days,
whereas 50 mM chloroquine was added for the final 16
hours. Live cells were stained with 50 nM LysoTracker
Red DND-99 (LY528, Invitrogen) in prewarmed medium
for 15 minutes at 37C. Cells were plated, fixed, per-
meabilized, and blocked using the same method as the E-
cadherin (CDH1) and vimentin (VIM) staining. Cells were
then incubated in primary Ab LC3 A/B (DU4C) (12741,Cell Signaling Technology) at one-to-100 ratio overnight
at 4C, carefully rinsed three times with PBS-T, and
incubated with secondary antibody Alexa Fluor-488
labeled goat anti-rabbit (A11008, Invitrogen, 1:200) for
1 hour at room temperature; it was then subsequently
washed four times with PBS-T before mounting with
ProLong Diamond Antifade Mountant with DAPI
(P36962, Molecular Probes). This protocol was adapted
from Kang et al.34 Images were obtained on a Leica TCS
SP8 confocal microscope using 100 objective lens
magnification (HC PL Apo STED white, oil, NA ¼ 1.4,
WD ¼ 0.13 mm). The co-localization intensity spatial
profile was obtained by drawing a one pixel-wide square
across the images, and the same area was selected for
the green and red channels for each image. The plot
profile function in ImageJ was then used to find the in-
tensity values that were plotted in GraphPad Prism.Autophagic Flux Experiments by Tandem Sensor
LC3 Constructs and Confocal Imaging
The Premo Autophagy Tandem Sensor RFP-GFP-
LC3B Kit (P36239, Thermo Fisher Scientific) was used
according to the manufacturer’s instructions. Ten thou-
sand cells were seeded on Poly-D-lysine coated cover-
slips (12 mm, 1.5 thickness, crystal-clear German glass
coverslips with Poly-D-lysine coating, Neuvito Corpora-
tion) in 24-well plates for 48 hours before incubation
with 10 mL of BacMam reagent (insect baculovirus with a
mammalian promoter containing tandem RFP-GFP-LC3B
DNA) for 24 hours. Cells were then treated with DMSO
(vehicle control), bemcentinib (0.8 mM), chloroquine (50
mM), or a combination of bemcentinib and chloroquine
for 24 hours. Rapamycin (200 nM) was applied as an
additional positive control. Cells were rinsed once with
PBS and fixed with 4% PFA in PBS for 15 minutes at
room temperature before mounting with ProLong Dia-
mond Antifade Mountant with DAPI (P36962, Thermo
Fisher Scientific). Images were obtained on a Leica TCS
SP8 confocal microscope using 100 objective lens
magnification (HC PL Apo STED white, oil, NA ¼ 1.4,
WD ¼ 0.13 mm).Lentiviral Expression Plasmids
Lentiviral expression plasmids encoding mCherry-
EGFP-LC3B were produced in the pLVX-Tight-Puro
backbone (Clontech Laboratories, Mountain View, CA)
using a Gibson Assembly of the individual PCR products.
Triple transfection of HEK293 packaging cells was per-
formed with either the p-LVX-Tight-Puro-mCherry-
EGFP-LC3B expression plasmid or with pLVX-Tet-On
Advanced transactivator expression plasmid, both
accompanied by the pMD2.G packaging plasmid and
pVSV-G envelope plasmid (Tronolab), as described
980 Lotsberg et al Journal of Thoracic Oncology Vol. 15 No. 6previously.35 Target cells were subsequently simulta-
neously transduced with transactivator and mCherry-
EGFP-LC3B encoding viral particles in the presence of
4 mg/mL protamine sulfate (P4020, Sigma-Aldrich).
Transgene expression was induced by doxycycline (1
mg/mL, 631311, Clontech), and cell populations were
sorted twice by fluorescence-activated cell sorting
(FACS) (Sony SH800) to obtain a cell population con-
taining a high percentage of stably transduced cells with
medium to high transgene expression. Stably transduced
cells were subsequently used for the live cell confocal
imaging described below.Live Cell Confocal Imaging
We seeded 10,000 cells per well in four-well plates
(1m-Slide four-well IbidiTreat, Ibidi GmbH, Martinsried,
Germany) and allowed them to attach overnight before
treatment with DMSO (vehicle control), bemcentinib
(0.8 mM), or chloroquine (50 mM). All treatments were
done in the presence of doxycycline (1 mg/mL,
631311, Clontech) to induce transgene expression.
After 24 hours of treatment, cell culture medium was
exchanged with phenol red–free cell culture medium
(D5030, Sigma-Aldrich) supplemented with 5% FBS, 1
mg/mL doxycycline, and Draq5 (62254, Thermo Fisher
Scientific 1:1000), and the indicated concentrations of
vehicle (DMSO), bemcentinib, or chloroquine. Live cell
imaging was performed with a Leica TCS SP8 confocal
microscope equipped with a TokaiHit (Shizuoka, Japan)
tabletop incubator and CO2 control using 40 objec-
tive lens magnification (HC PL Apo motCORR CS2,
water, NA ¼ 1.1, WD ¼ 0.65 mm). Images were ob-
tained every 10 minutes with the following settings:
sequence 1: 488 nm laser, PMT detector (495–556
nm), gain 833 and 640 laser, HyD detector (650–750
nm); sequence 2: 561 laser, HyD detector (570–
625nm). Autofocus control was used to hold current
position, and a line averaging of two was applied for
all images.Long-Lived Protein Degradation Assay by Flow
Cytometry
For the quantification of autophagic long-lived protein
degradation, we performed a flow cytometry–based
protocol developed by Zhang et al.,36 with minor modi-
fications. In principle, L-azidohomoalanine (AHA) was
used as a surrogate for the essential amino acid L-
methionine. A click reaction between the incorporated
azide and fluorescently labeled alkyne renders long-lived
proteins fluorescently labeled for FACS quantification.
Cells were seeded in six-well plates at a density of 2.5 x
105 cells per well. The following day, the cells were
washed with prewarmed PBS and cultured in L-methionine–free RPMI1640 (R7513, Sigma-Aldrich) for
30 minutes to deplete the methionine reserves. The cells
were then pulsed with the Click-IT AHA (C10102, Sigma-
Aldrich) for 24 hours at a final concentration of 25 mM in
L-methionine–free medium supplemented with 5% FBS
and 2 mM L-glutamine (Sigma-Aldrich). After the pulse,
the AHA-containing medium was removed and the cells
were washed with 2 mL PBS with 2.5% FBS to remove
unincorporated AHA, and cultured in regular complete
RPMI1640 with 5% FBS and L-glutamine containing 10
times L-methionine (final concentration 2 mM) to pre-
vent reincorporation of AHA surrogate for 2 hours to
chase out the short-lived proteins. The cells were then
pretreated (as indicated in the figure legend, Fig. 5D)
for 16 hours in complete RPMI1640 with 5% FBS
and L-glutamine (Sigma-Aldrich) containing 10 times
L-methionine (Sigma-Aldrich). Then, the cells were
washed with either 2 mL complete RPMI1640 with 5%
FBS or Earle’s balanced salt solution (EBSS) with 0.1%
BSA two times, and both media were supplemented with
10 times L-methionine. The cells were then incubated
with the complete media or starvation media with
various treatments for 3 hours. After treatment, cells
were harvested with trypsin and fixed in 4% formalde-
hyde in PBS for 15 minutes at room temperature. After
fixation, cells were washed twice with PBS containing 3%
BSA and permeabilized with 0.5% Triton X-100 in PBS
for 20 minutes at room temperature. Finally, the cells
were washed in PBS and incubated in the click reaction
mixture for 2 hours at room temperature. A final con-
centration of 5 mM AF-488–labeled alkyne (A10267,
Invitrogen) in the copper-containing Click-IT reaction
buffer (C10269, Invitrogen) was used. After tagging and
washing, single-cell signal intensities were detected in
the fluorescence intensity-1 channel, and the ratio of
fluorescence intensity in treated cells to unlabeled con-
trol cells was calculated. Relative fluorescence intensity
was calculated as follows: (%) ¼ ([treated group MFI –
unstained control MFI) / (vehicle control group MFI –
unstained control MFI])  100. This represents the rate
of degradation of long-lived proteins at given time points.Detection of Autophagic Flux by CYTO-ID Flow
Cytometry Assay
A quantitative assay for monitoring the autophagic
activity at the single-cell level (CYTO-ID Autophagy
detection kit, ENZ-51031, Enzo Life Sciences, Farm-
ingdale, New York) was performed according to the
manufacturer’s instructions in combination with auto-
phagy induction and inhibition to measure the auto-
phagosome generation and clearance by live cell flow
cytometry by BD Accuri C6 flow cytometer (BD Bio-
sciences). In this assay, following 16 hours pretreatment,
June 2020 AXLi Abrogates Autophagy and Induces ICD 981starvation for 3 hours in EBSS supplemented with 0.1%
BSA was used for autophagy induction, and chloroquine
at a concentration of 50 mM for 16 hours treatment and a
final concentration of 300 mM for 3 hours was used to
inhibit the successful fusion between autophagosomes
and lysosomes. Induction and inhibition of autophagy
were performed in combination with the treatments, as
indicated in the figure legend (Fig. 5C).
Gene Expression Analysis of Human Lung
Adenocarcinoma (LUAD) and Lung Squamous Cell
Carcinoma (LUSC) Samples
We investigated the association between AXL
expression and autophagy score in The Cancer Genome
Atlas (TCGA) LUAD cohort (n ¼ 517) and the combined
LUAD and LUSC cohort (n ¼ 1018).37 Gene expression
values in fragments per kilobase of transcripts per
million mapped reads were downloaded from Broad
firehose, version 2016_01_28.38 Autophagy signatures
were downloaded from Gene Set Enrichment Analysis
Molecular Signatures Database v6.1,39,40 the Autophagy
database,41 and Human Autophagy Database (last
accessed: 2019 Apr 22; http://autophagy.lu/index.html).
Enrichment scores were subsequently estimated using R
v3.5.1, Bioconductor v3.8 GSVA v1.28.0.42
Transmission Electron Microscopy
For the preparation of treated cells for transmission
electron microscopy, cells were seeded in six-well plates
and treated with drugs, as indicated (7 days of treatment
with erlotinib and bemcentinib, then chloroquine was
added for the final 16 hours), washed twice with PBS,
and then fixed for 1 hour at room temperature in 2.5%
ultrapure glutaraldehyde in PBS. Postfixation was done
by 1% osmium tetroxide for 1 hour on ice, before
washing and dehydrating with ascending concentrations
of alcohol. Infiltration was carried out using ethanol with
propylene oxide (1:1 ratio) for 1 hour. Three individual
specimens per sample were collected and placed in fresh
resin and polymerized at 60C for 48 hours. Thick sec-
tions were cut at 1 mm and stained with 0.6% toluidine
blue in 0.3% sodium bicarbonate; 70 nm sections were
cut and stained with saturated uranyl acetate in 50%
ethanol followed by Reynolds lead citrate. Electron mi-
croscopy images were obtained using a Jeol JEM-1230
transmission electron microscope (Jeol, Tokyo, Japan).
Real-Time Growth Curve Measurement by
IncuCyte Confluence Measurement
The IncuCyte ZOOM microscope and software (Essen
Bioscience) were used to measure % confluence in real
time. Cells were seeded and treated with bemcentinib as
described, for the resazurin cell viability assays. Twoimages were taken per hour per well of the 96-well plate
by IncuCyte microscope using Nikon 10 objective lens
magnification. Percent confluence was quantified using
the IncuCyte software, and the settings for the quantifi-
cation of confluence measurements by the IncuCyte
software were optimized individually for the different
cell lines of the experiment and were given to the
various cell lines as per the following: HCC827 (seg-
mentation adjustment: 1.2; Hole fill: 100 mm2; adjust
size: –6 pixels; Filters: Area min: 100 mm2), ER3 (seg-
mentation adjustment: 1.5; Hole fill: 200 mm2; adjust
size: –1 pixels; Filters: Area min: 200 mm2), and ER10
(segmentation adjustment: 1.2; Hole fill: 100 mm2; adjust
size: –1 pixels; Filters: Area min: 200 mm2). Time-lapse
cytotoxicity assay to determine the cytotoxic effect of
staurosporine treatment in HCC827, ER3, and ER10 cells
was established using the IncuCyte CytoTox Green re-
agent 200 mM to stain the dead cells. Green area relative
to the percent confluence for each well was plotted ± SE.
Calculations where n equals three wells per condition
and four images per well per time point was done using
the IncuCyte software in accordance with the manufac-
turer’s instructions.AXL Silencing by siRNA Transfection
For siRNA transfection, HCC827 and ER3 cells were
seeded 2  105 cells per well in six-well plates and
allowed to adhere overnight. Cells were transfected with
Individual ON-TARGETplus AXL-siRNA#1, #2 (Dharma-
con, Lafayette, CO, J-003104-11 and J-003104-12,
respectively), or ON-TARGETplus Non-targeting siRNA
(Dharmacon, D-001810-01) at a final concentration of 10
nM in 2 mL culture medium per well, using HiPerFect
transfection reagent (Qiagen, Cat# 301704) in accor-
dance with the manufacturer’s protocol. After 24 hours,
the cells were treated with vehicle (DMSO), erlotinib (1
mM), or chloroquine (10 mM or 100 mM, as indicated) for
another 16 hours. After treatment, cells were harvested
and lysed with RIPA buffer with protease and phos-
phatase inhibitors, and knockdown was confirmed by
SDS-polyacrylamide gel electrophoresis and Western
blot analysis. The effect of AXL knockdown on the
regulation of autophagy was analyzed by Western blot-
ting as described for drug treatment studies.ATP Release Assay
Release of extracellular ATP was measured by the
luciferin-based ENLITEN ATP Assay System Biolumi-
nescence Detection Kit for ATP Measurement in excess
of luciferin and luciferase, as indicated by the manufac-
turer (FF2000, Promega). Beforehand, 100,000 cells per
well were seeded in 12-well plates in the serum-free
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Figure 1. AXL inhibition delays emergence of acquired resistance to the EGFR tyrosine kinase inhibitor erlotinib in vivo, and
AXL signaling is associated with a novel gene signature of post-treatment cancer cell persistence that correlates with
decreased patient survival. (A) The growth of human NSCLC HCC827 xenograft tumors in nude mice displays the expansive
growth of vehicle-treated and bemcentinib-treated tumors (terminated at d 75). The tumors were initially sensitive to
erlotinib treatment but tumors treated with erlotinib alone eventually regrew. Group mean tumor volumes and SE are shown.
(B) Zoomed segment from (A) showing mean tumor volumes of groups treated with erlotinib (50 mg/kg, once a day) or
erlotinib in combination with bemcentinib (erlotinib 50 mg/kg, once a day and bemcentinib 50 or 100 mg/kg, twice a day,
respectively). The graph displays the final phase of the experiment from day 100 until study termination of experiment at day
138, with 14 to 16 tumors per group. (C) Representative images of tumor–bearing mice treated with erlotinib (50 mg/kg, once
a day) or erlotinib in combination with bemcentinib (50 mg/kg, once a day, and 100 mg/kg, twice a day, respectively). (D)
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drugs as indicated for 24 hours in the presence of 50 mM
ecto-ATPase inhibitor (ARL67156, A265, Sigma-Aldrich).
Harvested samples were transferred to ice-cold Eppen-
dorf tubes and spun down at 3200 g for 5 minutes at
4C. The supernatant was transferred to a new ice-cold
Eppendorf tube and stored at –80C until assayed. Cell
medium was used for background subtraction. ATP-
driven chemiluminescence was recorded at 0.1 s with
a 1420 Multilabel Counter VICTOR3 (Perkin Elmer) with
the Wallac1420 software. Three biological replicates
were given per condition, and the biological replicate
was represented by the mean value of two technical
duplicates.HMGB1 Immunoassay
To evaluate the HMGB1 release from treated cells in
culture, 100,000 cells were allowed to adhere to 12-well
culture dishes overnight and then treated with the
indicated drugs for 72 hours. Serum-free cell culture
media containing 1% BSA was used for this experiment
to avoid the detection of HMGB1 from the serum. Su-
pernatants were collected after treatment, cleared from
dying cancer cells by centrifugation (800 g, 5 min), and
frozen at –80C or immediately analyzed for HMGB1
abundance. The HMGB1 quantification was performed
using an HMBG1 enzyme immunoassay kit (ST51011,
IBL International GmbH, Hamburg, Germany), according
to the manufacturer’s instructions, for high-sensitivity
range detection.Flow Cytometry
For the detection of AXL by flow cytometry, cells
were harvested by trypsin, washed with PBS containingFinal tumor volumes at termination of study (d 138) of individu
Differences between treatment groups (n ¼ 14–16 tumors pe
Tukey’s multiple comparisons test (**p  0.01). (E) HCC827 tum
51 days of treatment with vehicle or erlotinib (50 mg/kg, once
AXL (140 kDa), pAXL (Tyr779, 140 kDa), pAKT (Ser473, 60 kDa)
loading control. (F) GO analysis of the whole-ranked list of g
treated versus erlotinib-treated tumors harvested after 25 day
ware taking the whole-ranked list of deregulated genes into
redundant GO terms removed is displayed. The table is generat
GOrilla, and the “frequency” represents the proportion of this G
represents more general terms, whereas the lower represents
term is an outlier when compared semantically with the whole l
ranked based on “dispensability,” which is the semantic similari
assigned to a cluster. (G) Volcano plot displaying differentially
tween HCC827 tumors treated for 25 days with erlotinib (50 mg
(50 mg/kg, once a day, and 50 mg/kg, twice a day, respectively
(fold change) values and the y-axis specifies significance –log10
up-regulated genes are indicated. (H) Bemcentinib-induced t
negative regulation of MAPK activity (SPRY1, SPRY2, and SP
adenocarcinoma. Kaplan-Meier survival analysis with survival ti
Hazard ratio ¼ 0.38 (0.29–0.48). Logrank p ¼ 1.9E-15. ANOVA,1% BSA, and blocked in 5% goat serum in 1% BSA with
PBS for 20 minutes. The cells were then stained with
mouse monoclonal anti-AXL antibody (MAB154, R&D
Systems, Minneapolis, Minnesota) for 30 minutes at
room temperature, washed as above, and incubated with
AF488-conjugated secondary goat anti-mouse antibody
(A11029, Invitrogen) for 30 minutes at room tempera-
ture. The cells were washed and analyzed using a FACS
Accuri C6 flow cytometer (BD Biosciences). For the
detection of surface-exposed CALR, trypsinized cells
were fixed with 0.25% paraformaldehyde in PBS for 5
minutes on ice, washed in PBS, and subjected to indirect
immunofluorescence with a rabbit anti-CALR antibody
(mouse monoclonal anti-CALR antibody, PE-conjugated,
ab83220, Abcam). Ab91357 (Mouse IgG1, PE-
conjugated, Abcam) was used as an isotype control for
these experiments. Samples were run on an Accuri Flow
Cytometer (BD Biosciences), and data were analyzed by
Cytobank (Santa Clara, California).Statistics
Data were presented as mean values (± SD) or as fold
changes from a representative experiment, if not other-
wise indicated in the figure legends. In general, all sta-
tistical analyses were performed using the GraphPad
Prism 7 software (San Diego, California). For in vivo ex-
periments, comparison of tumor volumes between treat-
ment groups were performed by one-way ANOVA with
Bonferroni’s Multiple Comparison Test using the Graph-
Pad Prism 7 software. Survival was analyzed by Kaplan-
Meier estimation. Outliers were determined using
Grubbs’ test, also called the extreme studentized deviate,
with a significance level 0.01 (two-sided). The Spearman
correlation coefficient rank test was performed using
Matlab R2016b version 9.1.0.441655 (MathWorks;al HCC827 tumors for different treatment groups are shown.
r group) were calculated using one-way ANOVA followed by
ors from a separate in vivo experiment were harvested after
a day) to perform Western blot analysis for the expression of
, and vimentin (VIM, 57 kDa). GAPDH (37 kDa) is shown as a
enes differentially expressed in erlotinib and bemcentinib–
s of treatment. The list is computed using the GOrilla soft-
account. REViGO visualization of the GO terms and with
ed on the basis of the GO terms and associated p values from
O term in the underlying database; that is, higher frequency
more specific ones. The “uniqueness” measures whether the
ist. More unique terms tend to be less dispensable. The list is
ty threshold at which the term was removed from the list and
expressed genes (cutoff: 1.5-fold change and p < 0.01) be-
/kg, once a day) or combination of erlotinib and bemcentinib
) (n ¼ 6 tumors). The x-axis specifies the gene expression log2
(p value) for each gene. The position of selected down- and
ranscriptional changes in mesenchymal markers involved in
RY4) correlate with overall survival in patients with lung
me (mo) on the x-axis and survival probability on the y-axis.







Figure 2. Erlotinib-resistant subclones underwent epithelial-to-mesenchymal transition and up-regulation of AXL and are
characterized by resistance to apoptosis. (A) Erlotinib sensitivity of HCC827 parental cells and the erlotinib-resistant sub-
clones (ER3 and ER10) was measured by resazurin assay after 5 days of erlotinib treatment. The mean IC50 value for HCC827
cells was 5.6 nM, and greater than 10 mM for the two erlotinib-resistant subclones ER3 and ER10 (n ¼ 11–13, independent
experiments). (B) Representative confocal images of HCC827, ER3, and ER10 cells immunofluorescently labeled for epithelial
cell adhesion molecule E-cadherin (CDH1, green) and mesenchymal intermediate filament vimentin (VIM, red); DAPI nuclear
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to report statistical significance: (1) NS ¼ p greater than
0.05; (2) *p smaller than or equal to 0.05; (3) **p smaller
than or equal to 0.01; (4) ***p smaller than or equal to
0.001; and (5) ****p smaller than or equal to 0.0001.Results
AXL Signaling is Required for Acquired
Resistance to Erlotinib In Vivo
Acquired resistance to BRAF–targeting agents in
melanoma is shown to proceed through a two-step
process in which rare, transient, AXL-expressing drug-
resistant (AXL jackpot) cells persist on drug treatment
and lead to stable drug resistance without new muta-
tions.10 The prevalence of AXL expression in EGFRi-
resistant NSCLC indicates that this mechanism may be
an important step in acquired resistance to targeted
therapies in lung cancer.13,14,43 To address the role of
AXL in acquired resistance to erlotinib, we designed
three independent in vivo experiments. In the first
in vivo experiment, we aimed to evaluate whether inhi-
bition of the AXL–mediated signaling by the oral small
molecule AXL tyrosine kinase inhibitor bemcentinib
(BGB324) could delay the onset of erlotinib resis-
tance.44,45 In this experiment, animals harboring tumors
established from HCC827 (EGFRDelE746-A750) NSCLC cells
were randomly assigned to six treatment groups and
treated with one of the following: vehicle, erlotinib
monotherapy (50 mg/kg, once a day), bemcentinib
monotherapy (50 mg/kg or 100 mg/kg, twice a day), or
a combination of erlotinib (50 mg/kg) and bemcentinib
(50 mg/kg or 100 mg/kg) for 5 months (138 d). Animals
in the vehicle and bemcentinib monotherapy groups
were killed within 75 days owing to their large tumorstain (blue); scale bar: 50 mm. Single channel displays are show
HCC827 parental and ER cells using the indicated antibodie
mesenchymal markers N-cadherin (CDH2, 135 kDa), vimentin (V
loading control. (D) Relative resistance to apoptosis was measu
cells and ER10 cells upon 4 hours treatment with increasing dos
represents bioluminescence as photon flux (photons/s). One-w
comparisons test comparing every treatment against vehicle (D
cytotoxicity assay to determine the cytotoxic effect of staurosp
(stained with IncuCyte CytoTox Green reagent 200 mM) represe
for each well ± SE. Three wells per condition and four images pe
IncuCyte software. (F) Assessment of apoptosis induction in HC
staurosporine by Western blot; cleaved PARP (89 kDa), procasp
caspase 8 (CC8; 43, 41, and 18 kDa) expression is shown. HeLa
Actin (42 kDa) serves as a loading control. (G) High-dimensiona
resistant clone ER3 using a 22-parameter time of flight mass cy
tSNE33 created a 2D projection of the three cell lines on the ba
AXL, and PD-L1 expression. Each point in the Cytobank visual
representing a single cell (equal downsampling at 10,000 cell
cells within the viSNE plot is shown as viSNE contour plots color
color range represents the intensity of markers included in the C
lines in separate viSNE plots. DAPI, 40,6-diamidino-2-phenylind
death-ligand 1; tSNE, t-distributed stochastic neighbor embeddvolumes. As expected, established HCC827 tumors
responded to erlotinib treatment, showing an initial
rapid decrease in tumor burden—68% decrease within
10 days of treatment initiation (Fig. 1A). The maximal
antitumor response was maintained for 3 months
(Fig. 1A). However, after 100 days on erlotinib therapy,
tumor relapse was observed in 70% of the mice
belonging to the erlotinib treatment group (50 mg/kg,
once a day), confirming that the model closely mimics
the transient duration of response observed for the vast
majority of patients with NSCLC treated with erlotinib in
the clinic. Upon termination of experiment (138 d),
average recurrent tumor volumes had exceeded the tu-
mor volumes recorded at the start of therapy (Fig. 1A
and B). Although bemcentinib treatment alone exhibited
no effect on the HCC827 tumor growth in the nude mice,
statistically significant tumor growth delay (p < 0.01)
was observed in the bemcentinib-erlotinib combination
treatment groups (erlotinib 50 mg/kg once a day and
bemcentinib 50 mg/kg or 100 mg/kg twice a day). More
importantly, at the time of termination of the experi-
ment, maximal antitumor response comprising non-
palpable residual nodules was maintained (Fig. 1B and
D). The prominent effect of the AXL inhibitor bemcenti-
nib in this tumor model suggests that AXL signaling is
required for acquired erlotinib resistance in vivo in the
HCC827 model.AXL Signaling Is Associated With a Novel Gene
Signature of Post-Treatment NSCLC Cell
Persistence That Correlates With Decreased
Patient Survival
To evaluate whether AXL-mediated signaling was
activated by erlotinib treatment in vivo, we designed an in Supplementary Figure 1. (C) Western blot of lysates from
s for epithelial marker E-cadherin (CDH1, 135 kDa), and
IM, 54 kDa), and AXL (140 kDa). b-Actin (42 kDa) is shown as a
red by induction of caspase activity of the HCC827 parental
es of staurosporine by caspase 3/7 Glo luciferase assay. Y-axis
ay analysis of variance was followed by Dunnett’s multiple
MSO) control (*** p < 0.001, **** p < 0.0001). (E) Time-lapse
orine treatment in HCC827, ER3, and ER10 cells. Green area
nting dead cells is plotted relative to the percent confluence
r well per time point were used for the calculations using the
C827, ER3, and ER10 cells upon 24-hour treatment with 1 mM
ase 3 (32 kDa), cleaved caspase 3 (19, 17 kDa) and cleaved
cells were included as a positive control in this experiment.
l analysis of the HCC827 parental cell line and the erlotinib-
tometry (CyTOF) panel. Nonlinear dimensionality reduction,
sis of their E-cadherin (CDH1), vimentin (VIM), CD44, EGFR,
representation of data (viSNE plot) represents an ion-cloud
s per sample, 5000 iterations were applied). Distribution of
ed by density of ion clouds representing single cells. (H) The
yTOF panel and the distribution is shown for each for the cell
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Figure 3. Bemcentinib treatment reduces clonogenic survival of ER cells. (A) Representative images of crystal violet-stained
colonies from clonogenic survival assay of HCC827, ER3, and ER10 cells treated for 14 days with vehicle (DMSO), bemcentinib,
or erlotinib as monotherapy. (B) Survival fraction of HCC827, ER3, and ER10 cells after treatment as indicated in (A). Each
experiment was performed in triplicate (n ¼ 2, independent experiments). Data represent survival fraction ± SD. Colony area
was quantified using the “ColonyArea” plugin in ImageJ and one-way ANOVA was followed by Dunnett’s multiple comparisons
test comparing every treatment against vehicle (DMSO) control (***p < 0.001, ****p < 0.0001). (C) Growth curves for HCC827
parental cells and ER3 and ER10 erlotinib-resistant clones in response to increasing doses of bemcentinib as indicated. Real-
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from HCC827 (EGFRDelE746-A750) NSCLC cells were
treated with erlotinib (50 mg/kg, once a day) and har-
vested 51 days after the initiation of erlotinib treatment.
To decipher the molecular basis for the role of AXL in
acquired resistance to erlotinib, we analyzed the
expression and activation of AXL, and a panel of markers
for EMT. Residual erlotinib-treated tumors exhibited
increased AXL expression compared with the vehicle
controls and increased phosphorylation of AXL and AKT
indicated that persistent HCC827 cells up-regulated AXL
and relied on AXL-mediated signaling (Fig. 1E). To gain a
better understanding of the early changes in erlotinib-
and bemcentinib-erlotinib–treated tumors, we designed
a third in vivo experiment in which residual tumor
tissues were harvested at day 25 and processed for
transcriptomic analyses. Gene ontology (GO) analysis
was computed on the basis of the whole-ranked list
of genes (Fig. 1F) using the GOrilla software.46,47 The GO
term autophagy was reported as one of the top
biological processes affected by bemcentinib-erlotinib
co-treatment versus erlotinib alone in these tumors
(Fig. 1F). Bemcentinib and erlotinib co-treatment resul-
ted in down-regulation of several autophagy-associated
genes, including KLH24, PDK4 FBXO32, and CDKN1B
in the list significantly altered genes (cutoff: 1.5-fold
change and p < 0.01) (Fig. 1G, Supplementary
Table 1). Analysis of differentially expressed genes in
bemcentinib-erlotinib–treated tumors versus erlotinib-
treated tumors identified GO biological processes,
which included neutrophil chemotaxis, negative regula-
tion of the MAPK activity and positive regulation of in-
flammatory response, and apoptotic processes (Fig. 1G;
Supplementary Tables 1A and B). Bemcentinib treatment
induced transcriptional changes in negative regulators of
RAS/MAPK activity, including the sprouty family.48
Three sprouty family members (SPRY1, SPRY2, SPRY4)
were up-regulated upon treatment with bemcentinib
in combination with erlotinib versus erlotinib alone.
A higher expression of SPRY1, SPRY2, and SPRY4, as
observed on bemcentinib treatment, correlated with
better overall survival in patients with LUAD (Fig. 1H).
SPRY2 expression has been shown to be consistently
lower in NSCLC tissue when compared with the corre-
sponding normal lung epithelium,49 whereas SPRY4 was
recently reported to correlate with AXL-mediatedtime measurements were performed over a time course of 120
the IncuCyte software are shown on the y-axis. The mean value
experimental condition. (D) Relative resistance to apoptosis w
HCC827 parental cells, ER3, and ER10 cells on treatment as indi
s) was measured, and fold change relative to vehicle control
Dunnett’s multiple comparisons test comparing every treatme
analysis of variance.osimertinib resistance.50 The role of the complex MAPK
signaling pathway in the regulation of autophagy is
context-dependent and has not yet been fully
described.51 Elucidation of the signaling cascades that
regulate autophagy and its mechanisms will therefore be
highly beneficial to disease treatment and prevention.Erlotinib-resistant NSCLC Cells Display
Epithelial Plasticity and Broad Resistance to
Apoptosis
To better understand the basis for AXL-mediated
drug resistance and survival, we examined the pro-
survival effects of AXL signaling in independent
erlotinib-resistant HCC827 cell clones (ER3, ER10) that
do not have secondary mutations in EGFR associated
with erlotinib resistance (e.g., T790M).13,14,52,53 As ex-
pected, HCC827 parental cells were extremely sensitive
to erlotinib (IC50z 6 nM), whereas ER3 and ER10 were
unaffected by erlotinib at concentrations up to 10 mM
(Fig. 2A). We observed a morphologic switch in the
epithelial HCC827 cells from a cobblestone-like shape in
the parental HCC827 cells to a spindle-like shape in the
ER cells. We then determined that the morphologic
switch was accompanied by induction of EMT hallmarks,
including down-regulation of E-cadherin (CDH1), up-
regulation of N-cadherin (CDH2) and vimentin (VIM),
and profound up-regulation of AXL in the ER cells
compared with the parental cells (Fig. 2B and C,
Supplementary Figs. 1, 2A, and B).13,14,52,53 Immunoflu-
orescence single channel displays are shown in
Supplementary Figure 1. The combination of apoptosis
assays and time-lapse experiment established that the
parental cells were more sensitive to induction of
apoptosis than the erlotinib-resistant clones under the
conditions and time points tested. Luminescence-based
caspase 3/7 assay (Fig. 2D), time-lapse evaluation of
cell death on staurosporine treatment (Fig. 2E), and
Western blot for cleaved caspase 3, cleaved caspase 8,
and cleaved poly (ADP-ribose) polymerase (Fig. 2F) are
shown.AXL Is a Unifying Marker for Drug Resistance and
Plasticity in the Resistant NSCLC Clones
To better understand the phenotypic and signaling
heterogeneity within the HCC827 and ER cellhours, and percent confluence measurements calculated by
of six replicate wells per condition with SE is shown for each
as measured by caspase 3/7 Glo luciferase activity assay in
cated for 24 hours. Bioluminescence as photon flux (photons/
(DMSO) is given (y-axis). One-way ANOVA was followed by
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Figure 4. AXL expressing erlotinib-resistant NSCLC cells are characterized by an increased cytoprotective autophagic flux
that is abrogated by inhibition with the selective AXL inhibitor bemcentinib and gene silencing by AXL siRNA. (A) Relative
protein levels of p62 (SQSTM, 62 kDa) and LC3A/B (LC3-I 17 kDa, LC3-II 19 kDa) were assessed in lysates of HCC827, ER3, and
ER10 cells by Western blot. b-Actin (42 kDa) is shown as a loading control. (B) HCC827 parental cells and ER3 cells grown in
complete medium or starved in EBSS (with 0.1% BSA in the absence or presence of chloroquine) were stained by the Cyto-ID
probe and analyzed by flow cytometry. MFI ± SD is shown. (C) Transmission electron micrographs of HCC827 and ER10 cells
with or without the autophagy inhibitor chloroquine (50 mM, 16 h); scale bar: 500 nm. (D, E) Representative transmission
electron microscopy images of erlotinib-resistant ER3 cells treated with erlotinib (D; 1 mM) alone or in combination with the
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profiling with a 22-marker antibody panel
(Supplementary Table 2). Nonlinear dimensionality
reduction by the tSNE algorithm was performed and 2D
viSNE projections of the three cell lines were created on
the basis of their E-cadherin (CDH1), vimentin (VIM),
CD44, EGFR, AXL, and programmed death-ligand 1
expression using Cytobank software (Fig. 2G). The viSNE
distribution revealed that the epithelial HCC827 cells
form a distinct cluster from the mesenchymal (E-cad-
herin low, vimentin high) erlotinib-resistant cells
(Fig. 2G and H, Supplementary Fig. 4A–C). Cell signaling
differed dramatically between the parental HCC827 and
ER populations (Fig. 2H, Supplementary Fig. 4A and B).
More importantly, the erlotinib-resistant cells exhibited
loss of pPLCy, pSTAT5, and EGFR/pEGFR expression and
strong AXL expression consistent with erlotinib resis-
tance (Fig. 2H, Supplementary Fig. 4A and C). AXL
signaling supports a unique pro-survival mode in drug-
resistant cells. We conducted viability assay to evaluate
the dose-response of erlotinib and bemcentinib, and the
Bliss independence analysis was applied to determine
potential synergy between the drugs in HCC827 and ER
cells upon 5 days treatment.27 Interestingly, this analysis
reported that erlotinib and bemcentinib action is inde-
pendent and exert an additive effect on ER cell viability
(Supplementary Fig. 3A–D). Clonogenic assays revealed
that bemcentinib treatment was sufficient to block ER
cell colony formation, revealing AXL dependence under
these conditions (Fig. 3A and B). Real-time growth curve
measurements for HCC827 parental cells and ER3 and
ER10 erlotinib-resistant clones in response to increasing
doses of bemcentinib were performed over a time course
of 120 hours (Fig. 3C), and revealed that the effect of
bemcentinib under these conditions is caused at least in
part by growth arrest (Fig. 3C). Bemcentinib treatmentsmall molecule AXL inhibitor bemcentinib (E; 0.8 mM) for 7 day
presence of autophagosomes (A) and autolysosomes (AL) are sho
for 40,000 magnification, and 60,000 magnification images.
kDa) and the nonlipidated (LC3-I, 17 kDa) and the lipidated (LC
cells treated for 24 hours under various treatment conditions a
kDa) is shown as a vehicle control. (G) Quantification of LC3A/
total protein using Bio-Rad stain-free imaging technology. Da
expression level of the HCC827 vehicle (DMSO)-treated sample.
AXL by siRNA in erlotinib-resistant ER3 cells. Western blot anal
specific knockdown of AXL by two siRNA constructs (siAXL #1 and
knockdown with vehicle (DMSO) or erlotinib (1 mM) treatment
dated (LC3-II, 19 kDa) forms of LC3A/B in the ER3 chloroquine
terations upon interrupted autophagic flux. Housekeeping prote
in this experiment. (I) Staining of the erlotinib-resistant ER3 cell
antibody reveals the presence of lysosomes (red puncta), a
puncta) in cells treated with erlotinib (1 mM), bemcentinib (0.
indicated 16 hours before fixation and staining. Scale bar; 10
images is shown. Marker in zoomed insert in (I) indicates the sel
conditions is 1 pixel high and 130 pixels wide. Fluorescence inten
is presented. BSA, bovine serum albumin; EBSS, Earle’s Balancdid not induce caspase 3/7 activity at 24 hours in ER3
cells (Fig. 3D). Caspase 3/7 assays (Fig. 3D) and Western
blot analysis for detection of induced apoptosis
(Supplementary Fig. 3E) of HCC827 parental cells and ER
cells treated for 24 hours with combinations of erlotinib
and bemcentinib verified that the treatment combination
did not induce prominent apoptosis at the earliest time
points, and only at the highest doses in ER10 cells. Taken
together, these data suggest that AXL signaling supports
a unique pro-survival mode in drug-resistant cells, that
AXL inhibition induces growth arrest, and that cell death
is induced at increased doses and time point. Repre-
sentative images of HCC827 and ER3 on various con-
centrations of bemcentinib 48 hours after treatment
initiation is shown in Supplementary Figure 2C. Time-
lapse videos from IncuCyte monitoration of HCC827
and ER3 cells upon treatment with bemcentinib are
available through this link (web-link with time-lapse
video will be made available to the readers),
Erlotinib-Resistant NSCLC Cells Display an
Increased Autophagic Flux
As the ER cells were more susceptible to undergo
apoptosis at the earliest time points compared with
parental cells (Fig. 2D), we next aimed to assess whether
the less sensitive AXL-expressing ER cells were also
characterized by an increased autophagic flux. Lipidation
of microtubule–associated proteins 1A/1B light chain 3
A/B (MAPLC3A/B, hereafter referred to as LC3A/B, and
in the figures LC3 for short) is frequently used as a
surrogate marker for disrupted autophagic flux54). On
induction of autophagy, the cytosolic form of the
ubiquitin-like protein LC3A/B (LC3-I) is conjugated to
phosphatidylethanolamine in the autophagic membrane
(LC3-II), and remains bound to autophagic vesicles
throughout the pathway, therefore the ratio betweens. On combination treatment, massive vacuolization and the
wn; scale bar; 5 mm for 4000 magnification images, 500 nm
(F) Western blot analysis of protein levels of p62 (SQSTM, 62
3-II, 19 kDa) forms of LC3A/B in the HCC827, ER3, and ER10
s indicated (1 mM erlotinib, 0.8 mM bemcentinib). b-Actin (42
B levels shown in (F). Normalization was performed against
ta are presented as fold change normalized against LC3-I
(H) Alterations in LC3A/B lipidation on specific knockdown of
ysis to verify the reduced protein levels of AXL (144 kDa) on
siAXL #2) versus control siRNA (siCtrl). Combination of siRNA
is also shown. The nonlipidated (LC3-I, 17 kDa) and the lipi-
treated samples are shown to indicate expected LC3A/B al-
in b-Actin (42 kDa) is shown as a control for loading accuracy
s by LysoTracker (red DN-99) in combination with anti-LC3A/B
utophagosomes (green puncta), and autolysosomes (yellow
8 mM), or both for 7 days. Chloroquine (50 mM) was added as
mm. (J) Co-localization intensity profiles from the zoomed
ected area analyzed and the marker used for all experimental
sity (y-axis) along the x-position (x-axis) of this selected area













































































































Figure 5. The specific AXL inhibitor bemcentinib inhibits the high premortem autophagic flux of the erlotinib-resistant cells.
(A) Dynamics of autophagosome formation and subsequent fusion with lysosomes to form autolysosomes was assessed by
Premo Autophagy Tandem Sensor RFP-GFP-LC3B experiment. ER10 cells transfected with RFP-GFP-LC3B tandem sensor were
treated as indicated for 24 hours with vehicle (DMSO), rapamycin (200 nM), bemcentinib (0.8 mM), or chloroquine (50 mM).
Representative confocal images are shown. Scale bar: 10 mm. (B) Schematics for the assay described above. The LC3-
associated autophagosomes seem yellow because of the simultaneous expression of both RFP and EGFP under neutral pH,
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of autophagy.55 We found that compared with HCC827
cells, both ER3 and ER10 cells exhibited increased
expression of LC3A/B, and, in particular, an increase in
the membrane-bound form LC3-II (Fig. 4A). A shift in
LC3A/B from the cytosolic form LC3-I to the lipid-bound
form LC3-II is usually associated with increased auto-
phagosome formation but could also indicate a block in
fusion of autophagosomes with lysosomes. Thus, in or-
der to draw conclusions regarding the autophagic flux,
the formation of autophagic compartments in HCC827
cells and erlotinib-resistant ER3 cells was further
quantified by a flow cytometry–based selective detection
of autolysosomes and earlier autophagic compartments
using the Cyto-ID detection probe to measure autophagic
activity. The Cyto-ID assay allow efficient measurement
of the dynamic balance between autophagosome gener-
ation and clearance. Chloroquine inhibits autophagy by
preventing lysosomal acidification, decreasing
autophagosome-lysosome fusion, and consequently re-
duces lysosomal protein degradation.56 Interestingly, the
starvation–induced autophagic flux was significantly (p
 0.0001) increased in ER cells when compared to
HCC827 parental cells (Fig. 4B). Morphometric trans-
mission electron microscopy confirmed increased
vacuolization in ER cells upon chloroquine treatment
(Fig. 4C), further strengthening the notion that the
autophagic flux is increased in the erlotinib-resistant
cells.
Moreover, we observed a massive vacuolization and
accumulation of autophagic vesicles (autophagosomes
and autolysosomes) in ER cells after 7 days treatment
with erlotinib and bemcentinib, compared with erlotinib
alone (Fig. 4D and E). Next, we evaluated the expression
of autophagy markers in erlotinib–sensitive versus
erlotinib-resistant cells in response to AXL inhibition. We
observed a shift from cytosolic LC3-I to lipidated LC3-II
in both HCC827 parental cells and ER cells after bem-
centinib treatment, suggesting that AXL inhibition in-
terferes with autophagy independently of erlotinib
(Fig. 4F and G). In order to evaluate whether bemcenti-
nib mediated effect on autophagy was specific to inhi-
bition of AXL, we performed siRNA mediated genetic(B) as on the fusion of the LC3-associated vesicles with the lysoso
the loss of fluorescence from the acid–sensitive EGFP fluorochro
in ER3 cells by measuring the balance of autophagosome forma
[DMSO], 50 mM chloroquine [CQ], 1.2 mM bemcentinib, 10 mM e
with 0.1% BSA for 3 hours (in the presence of treatment). Re
compared with the vehicle-treated cells in complete cell cultur
3). Unpaired t test (****p < 0.0001). (D) Flow cytometry Click-IT
ER3 cells pretreated as indicated for 16 hours with bemcentinib
0.1% BSA for 3 hours (in the presence of treatment). The alkyne
starved samples relative to the vehicle-treated (DMSO) cells i
(****p < 0.0001). BSA, bovine serum albumin; EBSS, Earle’s Balsilencing of AXL. Upon successful knockdown of AXL by
siRNA, the levels of lipidated LC3 (LC3-II) were mark-
edly increased compared to siCtrl samples and compa-
rable to the chloroquine treated positive control samples
(Fig. 4H).
Furthermore, co-localization of lysosomes and LC3-
positive vesicles confirmed the massive accumulation
of LC3-positive autophagosomes, lysosomes, and corre-
sponding fused autolysosomes in the erlotinib- and
bemcentinib-treated cells (Fig. 4I). Although inhibition of
autophagic flux with chloroquine 16 hours before fixa-
tion and staining caused a substantial accumulation of
LC3 and LysoTracker-positive vesicles in the erlotinib-
treated cells, no further accumulation of LC3 and Lyso-
Tracker double-positive vesicles was observed on
addition of chloroquine to cells co-treated with erlotinib
and bemcentinib, indicating that bemcentinib treatment
abrogated the autophagic degradation. Co-localization
intensity spatial profiles support these observations
(Fig. 4I and J).
AXL Inhibition Abrogates the Elevated
Premortem Autophagic Cell Flux in Erlotinib-
Resistant Cells
To dynamically monitor the formation of autopha-
gosomes versus autolysosomes over time in the absence
or presence of chloroquine, we utilized the Autophagy
Tandem Sensor RFP-GFP-LC3B probe (Fig. 5A and B).
When autophagic flux is normal, the fusion of autopha-
gosomes with acidic lysosomes resulted in the formation
and acidification of the fused autolysosomes. Owing to
the nature of the fluorescent probes of the tandem
sensor, autophagosomes will seem yellow (GFP þ RFP)
whereas autolysosomes seem red (RFP) owing to the
quenching of pH-sensitive GFP fluorochrome in the
acidic autolysosome (Fig. 5B). As shown in Figure 5A,
bemcentinib treatment of ER cells increased the
numbers of both yellow and red RFP-GFP-LC3B puncta,
in contrast with chloroquine treatment, which
completely inhibited the formation of red puncta
(Fig. 5A). The mTOR inhibitor rapamycin induces auto-
phagic flux and was included as a control. To further
elucidate how bemcentinib affects autophagic flux, weme, the resultant autolysosomes express RFP only because of
me under acidic conditions. (C) Autophagic flux was assessed
tion and clearance by pretreating the cells 16 hours (Vehicle
rlotinib). Autophagy was induced through starvation in EBSS
lative green fluorescence intensity from the Cyto-ID probe
e medium is given for a representative experiment ± SD (n ¼
AHA chemistry–based long-lived protein degradation assay of
1.2 mM or Bafilomycin A 50 nM, before starvation in EBSS with
-AF488 fluorescence intensity ± SD (n ¼ 3) was given for the




HCC827 81 105 107 988
HCC827ER3 95 272 118 531
HCC827ER10 122 854 218 819
MHC-I DMSO/MFI Bem/MFI
HCC827 921 213 1 178 215
HCC827ER3 489 223 576 377
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Figure 6. AXL is widely associated with positive regulation of autophagy signatures in human NSCLC transcriptome samples,
and bemcentinib treatment induces programmed cell death displaying hallmarks of immunogenic cell death with the release
of DAMPs (A–D) The correlation between AXL mRNA (fragments per kilobase of transcripts per million mapped reads; log2, x
axis) and four individually generated autophagy gene signatures (enrichment score, y axis) in human patient samples from
TCGA lung adenocarcinoma cohort (n ¼ 517). Correlation Rho and p value was computed by Spearman correlation coefficient
rank test. Correlation between AXL (FKPM log2) (x-axis) and enrichment score (y-axis). (A) Positive regulation of autophagy
gene expression signatures from the Human Autophagy Database (http://autophagy.lu/index.html), (B) MSigDB v6.1.39 (C)
Kumar Autophagy Network enrichment score,40 (D) the Autophagy database.41 (E) Release of extracellular ATP after 24 hours
treatment as indicated was measured by ATP luciferase assay for HCC827 parental cells and erlotinib-resistant clone ER3.
ER10 cells responded similar to ER3 cells (data not shown). Fold change values of extracellular ATP normalized against vehicle
control (DMSO) is shown for a representative experiment (n ¼ 4). One-way analysis of variance was followed by Dunnett’s
multiple comparisons test comparing every treatment against vehicle (DMSO) control (* p < 0.05, ****p < 0.0001). (F) Release
of HMGB1 after 72 hours treatment as indicated was measured by ELISA for HCC827 parental and ER3 cells. Parental cells
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doxycycline-inducible mCherry-EGFP-LC3B construct.
This enabled live cell imaging and time-lapse studies
visualizing real-time dynamics of autophagic vesicles on
pretreatment, as indicated (Supplementary Fig. 5). The
vehicle (DMSO) treated ER10-mCherry-EGFP-LC3B cells
displayed a moderate to low level of LC3B–positive ves-
icles, and during the 120-minute course of the time lapse,
the color of individual puncta did not change from yellow
to red at a constant rate. Furthermore, newly formed
yellow puncta were seen, indicating that the autophagic
flux was retained (Supplementary Fig. 5, lower panels).
ER10-mCherry-EGFP-LC3B cells treated with bemcenti-
nib (Supplementary Figure 5, middle panels) did, how-
ever, seem similar to cells treated with chloroquine,
showing increased frequency of yellow autophagosomes
and a prominent decrease in the movement and transi-
tion from yellow to red LC3-associated puncta, indicating
that fusion between autophagosomes and lysosomes is
compromised on bemcentinib or chloroquine treatment
(Supplementary Fig. 5).
The Cyto-ID assay allowed efficient measurement of
the dynamic balance between autophagosome genera-
tion, and clearance in ER3 cells treated with bemcentinib
in the presence or absence of autophagy inducers or
inhibitors (starvation and chloroquine, respectively). As
expected, no significant alteration was detected in ER3
cells cultured in starvation medium (EBSS with 0.1%
BSA) for 3 hours relative to culture in complete medium,
consistent with an uninterrupted flux in both conditions.
A significant increase in the relative fluorescence in-
tensity was detected in the starved cells when auto-
phagic degradation was inhibited by chloroquine,
indicating that the autophagic flux is intact in the ER3
cells (Fig. 5C). The relative fluorescence intensity was
also significantly increased on bemcentinib treatment of
the starved ER3 cells compared with the vehicle-treated
controls (Fig. 5C), confirming that bemcentinib abrogates
the balance between autophagosome generation and
clearance.
To further corroborate our findings, we took
advantage of a flow cytometry–based assay to quantifywere treated with erlotinib (8 nM) with or without bemcentinib
bemcentinib (0.8 mM). ER10 cells responded similar to ER3 ce
corresponding resazurin measurement for each well, and furthe
line. Data are shown for a representative experiment (n ¼ 4
multiple comparisons test comparing every treatment against v
assessment of extracellular calreticulin (CALR). Histograms of E
for all cell lines from a representative experiment is shown in
with 0.8 mM bemcentinib, and ER3 and ER10 cells with 1.2 mM
tocompatibility complex 1 assessed by flow cytometry after 7
centinib (0.8 mM for HCC827 parental cells, 1.2 mM for ER-cells).
values for all cell lines are given in the corresponding table. AT
mobility group box 1; MFI, median fluorescence intensity; M
Database; TCGA, The Cancer Genome Atlas.the degradation of long-lived proteins, known to occur
predominantly through autophagy. The methionine
analogue AHA was incorporated into newly synthesized
proteins during a long pulse, followed by a chase to
degrade short-lived proteins. The long-lived protein
degradation was then evaluated at the single-cell level
upon autophagy stimulation by starvation. Specific la-
beling of the incorporated AHA with a fluorescently
labeled alkyne, was followed by flow cytometry analysis.
Using this assay, we reported that bemcentinib treat-
ment significantly reduced the starvation–induced
degradation of long-lived proteins in ER3 cells when
compared with the vehicle-treated starvation controls
(Fig. 5D). Bafilomycin A, an inhibitor of the lysosomal
proton pump, inhibits fusion between autophagosomes
and lysosomes, and was included as a control in these
experiments.
The H1975 cell line harbors the T790M gatekeeper
mutation predictive of erlotinib resistance. NSCLC cells
harboring the T790M mutation can be targeted by third-
generation EGFR TKIs, e.g. rociletinib (CO-1686). AXL
has recently been shown to confer intrinsic resistance to
osimertinib and promote the emergence of osimertinib
tolerant cells.50 Thus, we aimed to evaluate if autophagy
was deregulated in the rociletinib-resistant (COR) clones
(COR1-1 and COR10-1) versus the H1975 parental cells
(Supplementary Fig. 6). Similar to what we observed in
the HCC827 model, development of acquired resistance
against rociletinib (Supplementary Fig. 6A) was accom-
panied with increased AXL expression (Supplementary
Fig. 6C and D) as well as a switch against a more
mesenchymal phenotype (Supplementary Fig. 6D and E).
Furthermore, we observed an increased expression of
LC3A/B in the drug-resistant COR1-1 and COR10-1
clones compared with the parental H1975 cells
(Supplementary Fig. 6D). When these cells were treated
with the AXL TKI bemcentinib (Supplementary Fig. 6B),
we observed an increase in LC3A/B by Western blot
analysis, and prominent vacuolization was observed by
lysotracker and LC3A/B co-staining (Supplementary
Fig. 6F and G), consistent with an abrogation of the
autophagic flux by bemcentinib treatment. These studies(0.8 mM), and ER3 cells were treated with erlotinib (1 mM) ±
lls (data not shown). Samples were normalized against the
r normalized against the vehicle control (DMSO) for each cell
). One-way analysis of variance was followed by Dunnett’s
ehicle (DMSO) control (****p < 0.0001). (G) Flow cytometric
R10 cells treated for 7 days as indicated are shown, and MFI
the corresponding table (n ¼ 4). HCC827 cells were treated
bemcentinib. (H) Alteration in the expression of major his-
days treatment with erlotinib (10 mM) with or without bem-
Histogram shown for ER3 cells. Median fluorescence intensity
P, adenosine triphosphate; CALR, calreticulin; HMGB1, high-
SigDB, Gene Set Enrichment Analysis Molecular Signatures
994 Lotsberg et al Journal of Thoracic Oncology Vol. 15 No. 6indicate that an increased flux is a mechanism broadly
associated with AXL up-regulation in NSCLC, and reports
that bemcentinib treatment abrogates the autophagic
flux in NSCLC cells resistant to first- and third- genera-
tion EGFR TKIs.
AXL Expression Is Widely Associated With
Autophagy in LUAD and LUSC
To determine whether AXL expression is broadly
correlated with positive regulation of autophagy in hu-
man adenocarcinomas, we evaluated correlation be-
tween AXL expression and positive regulation of
autophagy in human NSCLC. For this purpose, we first
analyzed RNAseq data from the TCGA LUAD cohort (n ¼
517),37 and these analyses established that AXL
expression is significantly associated with positive
regulation of autophagy gene expression signatures from
the Human Autophagy Database (http://autophagy.lu/
index.html), (Rho ¼ 0.3765, p < 1E-200, Fig. 6A). The
significant correlation between AXL expression and
autophagy was further validated by three additional
autophagy gene signatures generated from independent
datasets (Fig. 6B–D). These include autophagy signatures
downloaded from GSEA Molecular signature database
v6.139 (Rho ¼ þ0.5071, p < 1E-200, Fig. 6B), Kumar
Autophagy Network enrichment score40
(Rho ¼ þ0.3987, p < 1E-200, Fig. 6C), and the Auto-
phagy database41 (Rho ¼ þ0.3396, p ¼ 2.7E-15, Fig. 6D).
Furthermore, the strong positive correlation between
AXL expression and positive regulation of autophagy was
also confirmed in a combined group of LUAD and LUSC
from the TCGA cohort (LUAD þ LUSC, n ¼ 1018)37
(Spearman correlation Rho ¼ þ0.5017, p < 1E-200).Bemcentinib Induces Immunogenic Cell Death in
Erlotinib-Resistant Cells
ICD is characterized by active secretion of ATP,
exposure of CALR on the outer leaflet of the plasma
membrane, and the release of the high-mobility group
box 1 (HMGB1) protein. Premortem autophagy is an
essential determinant of the immunogenicity of drug-
induced cancer cell death by affecting the secretion of
ATP. On the basis of our findings above, we evaluated
whether bemcentinib treatment resulted in ICD in the ER
cells by measuring the release of ATP in addition to the
two other DAMPs; HMGB1 and surface-exposed CALR
(Fig. 6E–G). Using a luciferase–based assay, we evaluated
the release of ATP from ER cells treated with erlotinib
and bemcentinib for 24 hours, either as single agents or
in combination. We found that ATP secretion was
significantly (p < 0.0001) increased in the erlotinib-
resistant clones treated with the combination of erloti-
nib and bemcentinib (Fig. 6E). The release of the ATPdamage signal into the extracellular space increased in a
dose-dependent manner (Fig. 6E).
HMGB1 secreted from dying cancer cells functions as
a potent DAMP, with the potential to attract antigen-
presenting cells to the tumor bed. ELISA was used to
assess the release of HMGB1 from cancer cells on
treatment with erlotinib and bemcentinib administered
as single agents or in combination for 72 hours. A sig-
nificant (p < 0.0001) increase in extracellular HMGB1
after bemcentinib treatment alone or in combination
with erlotinib was observed in the ER3 cells. The HMGB1
increase was not significant on erlotinib-bemcentinib
combination treatment in parental HCC827 cells
(Fig. 6F).
CALR is externalized at the cell surface on cells during
ICD, and this potent “eat me” signal promotes efficient
phagocytosis by dendritic cells, thereby facilitating tumor
antigen presentation and incitement of tumor-associated
antigen-specific cytotoxic T-cells. Externalized CALR was
monitored at the single-cell level byflowcytometry,which
exhibited an increase in the extracellular exposure of
CALR after bemcentinib treatment in erlotinib-resistant
ER10 cells (Fig. 6G). In addition, bemcentinib treatment
resulted in a moderate increase in major histocompati-
bility complex-1 (MHC-I) (Fig. 6H). Antigen presentation
by MHC-I is essential for adaptive immunity. Thus, three
potent regulators of immunogenicity were up-regulated
in the erlotinib-resistant tumor cells on treatment with
bemcentinib, indicating an alteration of the tumor im-
mune microenvironment beneficial for tumor cell recog-
nition and eradication by the immune system.Discussion
The sequence of events that lead to acquired resis-
tance after an initial antitumor response to targeted
agents is complex and remain poorly understood. Cur-
rent models envision that acquired drug resistance re-
quires both robustness, the ability to withstand
environmental and genetic variability, and evolvability or
the ability to acquire selectable and heritable phenotypic
changes.57 Adaptive intrinsic phenotypic plasticity of
cancer cells facilitates a robust drug tolerant, slow
cycling state, which eventually transitions to permanent
mutational resistance.7,57,58 We report that AXL kinase
activity is necessary to acquire resistance to long-term
erlotinib therapy in an in vivo model of mutant EGFR
NSCLC. This supports the notion that AXL signaling un-
derpins a critical pro-survival function necessary for
long-term tumor cell persistence that is prerequisite to
attain durable drug resistance. This was recently and
independently confirmed using a different AXL kinase
inhibitor (DS-1205), in which combinational treatment
with DS-1205 and the third-generation EGFR inhibitor
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compared with osimertinib treatment alone in an
HCC827 xenograft model.59 This is consistent with a
recent study showing that acquired resistance to BRAFi
in melanoma cells in vitro is derived from transient AXL-
expressing drug-resistant (AXL jackpot) cells.10 In addi-
tion, in NSCLC, a recent report suggests AXL as an
important contributor to overcome the initial drug
response against osimertinib.50 A current clinical trial
(NCT02424617) is evaluating bemcentinib in combina-
tion with erlotinib in EGFR-mutant NSCLC.
Several assays may be used to assess the autophagic
flux, and great efforts have been made to standardize the
nomenclature and the guidelines for monitoring auto-
phagy in different model systems.60 In this context, it is
important to note that monitoring autophagic elements
may be used as a surrogate marker for autophagy,
although that is not equivalent to monitoring the auto-
phagic flux per se.60 In multicellular eukaryotes, moni-
toring autophagic flux is particularly challenging, and it
is difficult to discriminate a block in the autophagic flux
from an increased flux based solely on available surro-
gate markers. Thus, care is needed when interpreting
these results, and these challenges have likely contrib-
uted to some of the seemingly contradictory findings in
the field.61 We report that AXL signaling supports
enhanced autophagic flux that prevents caspase-
mediated apoptosis.17 This observation is aligned with
previous reports linking EMT and erlotinib resistance to
an increased cytoprotective autophagic flux.17,62,63
Exactly how the increased autophagic flux interferes
with the cells ability to undergo apoptosis is still
not known. However, based on our single-cell high-
dimensional mass cytometry analysis, we hypothesize
that this cytoprotective property of AXL-expressing cells
may function independent of EMT. Indeed, AXL-
expressing erlotinib-resistant NSCLC cells report sub-
stantial phenotypic and cell signaling heterogeneity that
is incongruent with the prevailing bypass signaling
hypothesis of acquired EGFRi resistance.2 The close
correlation between AXL and CD44, and the anti-
clonogenic effect of bemcentinib on ER cells suggests
that AXL signaling mediates survival in the context of
stem cell–like plasticity that includes epithelial, mesen-
chymal, and intermediate epithelial-mesenchymal
states.6 Overall, these findings support the hypothesis
that these features are critical for the survival of rare
cancer cells under extreme stress induced by initial drug
exposure.18,19,62,64-66
We found that treatment with the selective AXL in-
hibitor bemcentinib abrogated the cytoprotective auto-
phagic flux and significantly inhibited the degradation of
long-lived proteins upon autophagy induced by starva-
tion, resulting in cell death with accumulated autophagicvacuoles in the cytoplasm. Taken together, our results
support a model in which AXL-mediated signaling sus-
tains a high autophagic flux, which is disrupted when
AXL signaling is inhibited, either by the small molecule
AXL inhibitor bemcentinib or siRNA mediated knock-
down. AXL has previously been linked to autophagy in a
study of acute liver injury in mice, in which AXL was
reported to induce autophagy in macrophages after
interaction with its ligand GAS6, mediated by MAPK
(mitogen-activated protein kinase) 14 activity.67 In the
immune system, AXL acts as an inhibitor of the inflam-
matory response to pathogens, and AXL together with
the other TAM receptors are important for efficient
efferocytosis of apoptotic cells.68 Because of the simi-
larities between the mechanisms of efferocytosis and
autophagy, one can speculate that the cancer cells exploit
the physiological role of AXL in the regulation of effer-
ocytosis to induce an increased cytoprotective autopha-
gic flux to overcome acquired drug resistance against
anticancer therapeutics.
The exact mechanism underlying how high pre-
mortem autophagy contributes to ATP release remains
elusive, although it has been speculated that it might
preserve a bioenergetic status in which, despite massive
cellular damage and energy-consuming repair attempts,
high intracellular ATP levels are maintained.24 Targeting
AXL in ER cells induced a massive premortem autopha-
gic vacuolization in the erlotinib-resistant carcinoma
cells accompanied by ICD. One of the three hallmarks of
ICD is the active release of ATP by cells that are
committed to undergo, but have not yet succumbed to,
apoptosis. Intriguingly, our findings suggest that induc-
tion of ICD can be a potential benefit of AXL targeting of
drug-resistant EGFR-mutant NSCLC.
Recently, gene signatures enriched for wound healing
and EMT, including AXL up-regulation, were found to be
associated with innate resistance to programmed cell
death protein-1 blockade.21 In a recent study, we have
shown that the expression of AXL in the mesenchymal
NSCLC cells was correlated with an increased cancer
cell–intrinsic resistance to killing by both NK cells and
autologous CTLs. Notably, small molecule AXL targeting
potently sensitized mesenchymal lung cancer cells to
cytotoxic lymphocyte–mediated killing.21 Furthermore,
recent publications have suggested that AXL also sup-
presses proper antigen presentation by MHC-I, and that
targeting AXL could therefore mediate a favorable
reprogramming of the immune suppressive tumor
microenvironment.69,70 In this context, increased
immuno-adjuvanticity—the recruitment of professional
antigen-presenting cells to educate the naive CTL pop-
ulation—is critical to maximize the potential therapeutic
benefit of immune checkpoint blockade. Our novel
finding that bemcentinib is a potent inducer of ICD is of
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effect and alteration of the tumor immune microenvi-
ronment upon AXL inhibition. AXL has previously been
shown to suppress antigen presentation by MHC-I,
whereas AXL inhibition enhances cytokine release and
increases T-cell response in syngeneic models, resulting
in an elevated cytotoxic T-cell–dependent antitumor
immune response after radiation.69 Indeed, ongoing
clinical trials are evaluating AXL inhibition in combina-
tion with immune checkpoint inhibitors.70 To the best of
our knowledge, this is the first report to establish an
abrogated autophagic flux by AXL inhibition through
bemcentinib treatment. Monitoring autophagic flux
in vivo represents a challenge, and thus, uncertainty on
the role of autophagic flux as a regulator of DAMP
secretion still remains. Much remains to be learned
about the role of autophagy as a mediator of adju-
vanticity and of polarization of cancer cell phenotypes
and immune cell compartments in complex tumor im-
mune microenvironments.61 Despite the challenges in
monitoring DAMPs in vivo, and the obvious limitations of
the nude mouse model used in this study, particularly
with respect to the inability to examine immune effector
cell infiltration, it is tempting to speculate that the ICD
observed in our study may explain the previously re-
ported favorable alteration of the tumor immune
microenvironment observed in syngeneic lung carci-
noma models on bemcentinib treatment.69,71,72 In one of
these studies, reduced tumor growth and significant
reduction of myeloid–derived suppressor cells were
observed in the tumors of the animals treated with a
combination of programmed cell death protein-1
signaling inhibitors and an AXL inhibitor,69,70 reinforc-
ing the concept that immune checkpoint therapies are
not effective unless an antitumor immune response is
generated. Together with the immunogenicity of cancers,
it is evident that proper adjuvanticity is required for a
robust initiation of the cancer immunity cycle, and
several clinical trial protocols are currently exploring the
potential clinical benefit of increasing adjuvanticity in
the context of immune checkpoint inhibitor treatment
regimens. The release of DAMPs, including cell-surface
translocation of CALR and the release of HMGB1 and
ATP represent hallmarks of immunomodulation. This
immunomodulation, in turn, promotes an immune
response toward the cancer cells through the recruit-
ment of antigen-presenting dendritic cells and immune
effector cells to the tumor bed. Thus, the immunogenic
form of cell death activates both the innate and adaptive
arms of the immune system by initiating the cancer
immunity cycle.73
In conclusion, we report that AXL signaling is
necessary for acquired resistance to erlotinib in vivo in a
model of mutant EGFR–driven NSCLC. Our results alsoreveal a positive correlation between AXL expression
and autophagy in a cohort of human LUAD and LUSC
samples and implicate a cytoprotective, AXL–dependent
autophagy-related mechanism that supports a robust
drug tolerant state from which permanent resistance can
emerge. It has been shown experimentally that surpris-
ingly few combinations of drugs exert a true synergistic
effect; however, some drug cocktails may exert their
superior efficacy by affecting heterogenous cellular
subpopulations.74,75 In the case of AXL inhibition as a
means of preventing emergence of EGFR inhibitor–
resistant cells, we cannot rule out that the inhibition of
resistance could be attributed to more effective initial
antiproliferative, pro-apoptotic effects. Nevertheless, the
prevention of emergent AXL-positive cell populations
with increased autophagy pro-survival signaling de-
serves further study. As recently reported by Schaffer
and colleagues, acquired resistance to BRAF–targeting
agents in melanoma were shown to proceed through a
two-step process in which rare, transient, AXL-
expressing drug-resistant (AXL jackpot) cells persisted
on drug treatment and led to emergence of stable drug
resistance without acquisition of new mutations.10 With
regard to the case in which the drugs affect the same cell,
the convergence of downstream signaling pathways
related to cell death might limit the efficiency of the
combined treatment.74,75 In these cases, the exploitation
of alternative modes of cell death, particularly cell death
with increased potential to elicit an immune response,
represents a promising therapeutic possibility.76,77 A
growing body of evidence demonstrates a central role
for autophagy in modulating adjuvanticity, which is an
essential component for increasing both natural and
therapy-induced immunosurveillance.61 Of note, abro-
gation of this cytoprotective autophagic flux by AXL
targeting resulted in ICD, which is expected in turn to
enhance antitumor immunity and potentiate anticancer
effects. This suggests that AXL-expressing EGFR
inhibitor–resistant NSCLC may be sensitive to AXL tar-
geting in combination with immunotherapy.78 Further
experiments are warranted to evaluate the contribution
of the alterations in the various immune cell compart-
ments to the clinical efficacy of AXL inhibition.Acknowledgments
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